Biotechnology
Filter News
Found 46,688 articles
-
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
8/13/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.
-
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
BioFluidica is Awarded NIH Grant Funding through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19
8/12/2021
BioFluidica, a privately held biotechnology company in conjunction with the University of Kansas, today announced they have been awarded a grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx Tech) program.
-
Can-Fite Announces $10.0 Million Registered Direct Offering
8/12/2021
Can-Fite BioPharma Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares
-
Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets
8/12/2021
Nimbus Therapeutics today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.
-
Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
8/12/2021
Monte Rosa Therapeutics, Inc. today reported business highlights and financial results for the second quarter, ended June 30, 2021.
-
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
8/12/2021
Frequency Therapeutics, Inc today announced business updates and financial results for the second quarter ended June 30, 2021.
-
Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/12/2021
Novan, Inc., announced its financial and operating results for the quarter ended June 30, 2021 and provided a corporate update.
-
Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results
8/12/2021
Sio Gene Therapies Inc., a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, provided a corporate update and financial results for its fiscal first quarter ended June 30, 2021.
-
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
8/12/2021
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its second quarter and year to date June 30, 2021 operating and financial results.
-
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
8/12/2021
Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.
-
iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.
-
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Talaris Therapeutics, Inc. reported financial results for the three- and six-month periods ended June 30, 2021, and provided an update on its business.
-
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
8/12/2021
PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call
-
Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs
8/12/2021
Ikena Oncology, Inc., a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, announced financial results for the quarter that ended June 30, 2021.
-
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
8/12/2021
Acasti Pharma Inc. provided a business update and announced its operating and financial results for the first quarter of fiscal 2022 ended June 30, 2021.
-
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
8/12/2021
Vivet Therapeutics, a clinical-stage biotechnology company, and Pfizer Inc. announced the U.S. Food and Drug Administration has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
-
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
8/12/2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-715 for the treatment of multiple myeloma.
-
Silence Therapeutics Reports Half-Year 2021 Results
8/12/2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, announced results for its half-year ended June 30, 2021.